Vaccine rollout halves infant RSV hospitalisations

Early data shows the government's $174.5m ”world-leading” free respiratory syncytial virus (RSV) immunisation program for babies and expecting mothers has been a major success.

Please login below to view content or subscribe now.

Membership Login